Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$31.37|
|52 Week High||US$27.23|
|52 Week Low||US$43.41|
|1 Month Change||5.20%|
|3 Month Change||-12.08%|
|1 Year Change||-5.82%|
|3 Year Change||-4.82%|
|5 Year Change||n/a|
|Change since IPO||114.86%|
Recent News & Updates
|ALBO||US Biotechs||US Market|
Return vs Industry: ALBO underperformed the US Biotechs industry which returned 26% over the past year.
Return vs Market: ALBO underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: ALBO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ALBO's weekly volatility (7%) has been stable over the past year.
About the Company
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis.
Albireo Pharma Fundamentals Summary
|ALBO fundamental statistics|
Is ALBO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALBO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-7.05|
|Net Profit Margin||-1,468.41%|
How did ALBO perform over the long term?See historical performance and comparison
Is Albireo Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALBO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALBO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALBO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALBO is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (3.3x).
How is Albireo Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALBO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALBO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALBO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALBO's revenue (58.4% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ALBO's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time
How has Albireo Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALBO is currently unprofitable.
Growing Profit Margin: ALBO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 44% per year.
Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ALBO has a negative Return on Equity (-119.55%), as it is currently unprofitable.
How is Albireo Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ALBO's short term assets ($195.3M) exceed its short term liabilities ($27.0M).
Long Term Liabilities: ALBO's short term assets ($195.3M) exceed its long term liabilities ($79.0M).
Debt to Equity History and Analysis
Debt Level: ALBO's debt to equity ratio (8.7%) is considered satisfactory.
Reducing Debt: ALBO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALBO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALBO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 48% each year.
What is Albireo Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALBO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALBO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALBO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Cooper (58 yo)
Mr. Ronald H. W. Cooper, also known as Ron, serves as Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 2015. He serve...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD3.46M) is above average for companies of similar size in the US market ($USD2.30M).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
Experienced Management: ALBO's management team is considered experienced (3.2 years average tenure).
Experienced Board: ALBO's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Albireo Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Albireo Pharma, Inc.
- Ticker: ALBO
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$604.055m
- Shares outstanding: 19.26m
- Website: https://www.albireopharma.com
Number of Employees
- Albireo Pharma, Inc.
- 10 Post Office Square
- Suite 1000
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 22:02|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.